The session featured the participation of Dr. Ana Belén Pérez Oliva, who presented the advances and possibilities offered by lipid nanoparticles for delivering  gene therapies and therapeutic molecules directly to affected blood cells.
This technology represents one of the most promising approaches within personalized medicine and nanotechnology applied to healthcare, as it could enable  more precise, effective, and less invasive treatments for patients with beta-thalassemia and other hemoglobinopathies.
At NANEMIAR, we support the dissemination of international scientific initiatives that promote the development of innovative therapies and encourage  collaboration among researchers, healthcare professionals, and organizations dedicated to the study of rare hematological diseases. We would also like to  sincerely thank HELIOS for the opportunity to participate in this webinar and contribute to the exchange of knowledge in this important research field.